Repurposed drugs not effective treatment for hospitalised COVID-19 patients, WHO says
WHO has said that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon had little or no effect when treating hospitalised patients with COVID-19.
List view / Grid view
News
COVID-19 pandemic to heighten sales of pharmaceutical spray drying
A new report has predicted that the COVID-19 pandemic will drive demand for pharmaceutical spray drying, boosting the market.
Study suggests dolutegravir is the optimal first-line HIV medication
Researchers comparing dolutegravir to efavirenz suggest dolutegravir increases viral suppression and has similar rates of adverse events.
The FDA requires changes to NSAID labelling
The FDA is requiring that the prescribing information for nonsteroidal anti-inflammatory drugs (NSAIDs) include warnings about potential foetal kidney problems if taken by women over 20 weeks pregnant.
Telstar’s centre in the UK consolidates its business growth with move to new higher-capacity modern installation
Specialised in aseptic and containment barrier Isolation technology systems, Telstar UK has seen increased demand for its products from all across the life sciences sector has grown significantly in the past few years.
Bioanalytical testing services market to become a $4.5 billion industry
A report found the rise in outsourcing, growing popularity of biologics and expanding acceptance of quality-by-design approaches would drive the market expansion.
SARS-CoV-2 vaccine safely induces an immune response in healthy volunteers
16 October 2020 | By
The Chinese COVID-19 vaccine candidate BBIBP-CorV elicited an antibody response in all recipients, according to preliminary Phase I/II trial data.
MHRA joins international regulatory consortium
By joining the Access Consortium, the MHRA will work together with agencies from Australia, Canada, Singapore and Switzerland to expedite therapeutic product approvals.
NIAID trial to identify potential COVID-19 treatments for further development
The adaptive ACTIV-5/BET study will test two monoclonal antibody therapies in hospitalised COVID-19 patients to establish if they warrant larger clinical trials.
US FDA approves the first Ebola virus treatment – Inmazeb
The US Food and Drug Administration (FDA) has approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of Zaire ebolavirus infection in adults and children.
First patient dosed in COVID-19 vaccine tablet clinical trial
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.
J&J pauses COVID-19 vaccine clinical trial after participant illness
J&J has paused its Phase III trial for its COVID-19 vaccine candidate following an unexplained illness in a study participant.
Celltrion COVID-19 antibody treatment to enter Phase III trial
Celltrion Group's CT-P59 antibody will be tested as a COVID-19 prophylactic in a Phase III clinical trial.
Dupixent® (dupilumab) significantly reduces severe asthma attacks in children, finds study
In combination with inhaled corticosteroids, the monoclonal antibody Dupixent improved lung function and reduced the rate of severe asthma attacks.
US enters agreement for experimental prophylactic COVID-19 antibody cocktail
The US government will develop and manufacture AstraZeneca’s investigational monoclonal antibody cocktail, AZD7442, a potential prophylactic treatment for COVID-19.
